Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Antonis E. Koromilas"'
Autor:
Dibyendu K. Panda, Xiuying Bai, Yan Zhang, Nicholas A. Stylianesis, Antonis E. Koromilas, Mark L. Lipman, Andrew C. Karaplis
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 24 (2022)
The Hippo pathway nuclear effector Yes-associated protein (YAP) potentiates the progression of polycystic kidney disease (PKD) arising from ciliopathies. The mechanisms underlying the increase in YAP expression and transcriptional activity in PKD rem
Externí odkaz:
https://doaj.org/article/805150cc024648f6bb0b0df97758d5bb
Autor:
Nour Ghaddar, Shuo Wang, Bethany Woodvine, Jothilatha Krishnamoorthy, Vincent van Hoef, Cedric Darini, Urszula Kazimierczak, Nicolas Ah-son, Helmuth Popper, Myriam Johnson, Leah Officer, Ana Teodósio, Massimo Broggini, Koren K. Mann, Maria Hatzoglou, Ivan Topisirovic, Ola Larsson, John Le Quesne, Antonis E. Koromilas
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The Integrated Stress Response (ISR) is a cytoprotective pathway upregulated in many cancers. Here the authors show that the activation of PERK/p-eIF2α arm of ISR enhances ERK phosphorylation through translation repression of DUSP6, thus resulting i
Externí odkaz:
https://doaj.org/article/c5184c726c2a4e1fa460c06a009a5df9
Autor:
Cedric Darini, Nour Ghaddar, Catherine Chabot, Gloria Assaker, Siham Sabri, Shuo Wang, Jothilatha Krishnamoorthy, Marguerite Buchanan, Adriana Aguilar-Mahecha, Bassam Abdulkarim, Jean Deschenes, Jose Torres, Josie Ursini-Siegel, Mark Basik, Antonis E. Koromilas
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is req
Externí odkaz:
https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e72
Autor:
Ryuhjin Ahn, Valérie Sabourin, Alicia M. Bolt, Steven Hébert, Stephanie Totten, Nicolas De Jay, Maria Carolina Festa, Yoon Kow Young, Young Kyuen Im, Tony Pawson, Antonis E. Koromilas, William J. Muller, Koren K. Mann, Claudia L. Kleinman, Josie Ursini-Siegel
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Tyrosine kinase signalling in cancer cells promotes immune evasion. Here, the authors show that tyrosine kinases engage scaffold protein Shc1 to promote immunosuppression in breast cancer by simultaneously activating STAT3 immunosuppressive signals a
Externí odkaz:
https://doaj.org/article/4564af3090224e7180bdbbc6e315baaa
Autor:
Valentina Gandin, Laia Masvidal, Marie Cargnello, Laszlo Gyenis, Shannon McLaughlan, Yutian Cai, Clara Tenkerian, Masahiro Morita, Preetika Balanathan, Olivier Jean-Jean, Vuk Stambolic, Matthias Trost, Luc Furic, Louise Larose, Antonis E. Koromilas, Katsura Asano, David Litchfield, Ola Larsson, Ivan Topisirovic
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-15 (2016)
Ternary complex (TC) and eIF4F complex assembly are rate-limiting steps in translation initiation that are regulated by eIF2α phosphorylation and the mTOR/4E-BP pathway. Here the authors show that the protein kinases mTORC1 and CK2 coordinate TC and
Externí odkaz:
https://doaj.org/article/3b23e374915e42abafd814b872f5dd1d
Autor:
Antonis E. Koromilas, Maria Hatzoglou, Shuo Wang, Arnold S. Kristof, Kirk A. Staschke, Arkady Khoutorsky, Urszula Kazimierczak, Zineb Mounir, Jothilatha Krishnamoorthy, Clara Tenkerian
Supplementary Fig.1 (A) Quality control of PERK T799 phosphospecific antibody. (B) Quality control of LLY-71 (clone 1-6) rabbit monoclonal antibody to human PERK phosphorylated at T982.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb33ca004ce4ffe933c09aa719d2e90
https://doi.org/10.1158/1541-7786.22514965.v1
https://doi.org/10.1158/1541-7786.22514965.v1
Autor:
Antonis E. Koromilas, George Simos, Kostas Pantopoulos, Leda Raptis, Suiyang Li, Hala Muaddi, Philippos Peidis, Efrosyni Paraskeva, Andreas I. Papadakis
Hypoxia within the tumor microenvironment promotes angiogenesis, metabolic reprogramming, and tumor progression. In addition to activating hypoxia-inducible factor-1α (HIF-1α), cells also respond to hypoxia by globally inhibiting protein synthesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57156bbabc712aa29041c821dad319b9
https://doi.org/10.1158/0008-5472.c.6501158.v1
https://doi.org/10.1158/0008-5472.c.6501158.v1
Autor:
Antonis E. Koromilas, George Simos, Kostas Pantopoulos, Leda Raptis, Suiyang Li, Hala Muaddi, Philippos Peidis, Efrosyni Paraskeva, Andreas I. Papadakis
Supplementary Figures 1-6 from eIF2α Kinase PKR Modulates the Hypoxic Response by Stat3-Dependent Transcriptional Suppression of HIF-1α
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a47573ca9101fac0210e6bb2ea7403d9
https://doi.org/10.1158/0008-5472.22385231
https://doi.org/10.1158/0008-5472.22385231
Autor:
Hyungdong Kim, Nour Ghaddar, Laleh Ebrahimi Ghahnavieh, Shuo Wang, Kwang-Jin Cho, Atsuo Sasaki, Antonis E. Koromilas
Publikováno v:
Molecular Cancer Research. 21:A022-A022
KRAS mutations appear with high frequency in colorectal, lung and pancreatic cancers, which are the three leading causes of new cancer deaths worldwide. Mutant KRAS is preferentially bound to GTP resulting in continuous cell proliferation. Mutant KRA
Publikováno v:
Molecular Cancer Research. 21:A017-A017
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) constitutes 80% of all lung malignancies with 15-25% attributed to mutations in the KRAS gene. KRAS mutations expose cells to stress-inducing conditions, e